Far red and near infrared light-mediated conditioning of tissues and/or blood to prevent reperfusion injury in endovascular therapies
Inventors
Lohr, Nicole • Salinger, Michael
Assignees
Publication Number
US-12318626-B2
Publication Date
2025-06-03
Expiration Date
2042-03-22
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Reperfusion injury is limited during endovascular therapies (e.g., revascularization and/or reperfusion of end organ tissues) by conditioning the tissues against reperfusion injury using an optical fiber catheter to deliver far red and near infrared (R/NIR) light to the tissues. The light may be multiple wavelength or single wavelength light, and may have one or more wavelengths selected from the range of 510 to 830 nm. The R/NIR light may be delivered concurrently with the endovascular therapy, or in other instances may be delivered before or after a particular therapy.
Core Innovation
The invention provides a method for conditioning tissues to reduce reperfusion injury during endovascular therapies by delivering far red and near infrared (R/NIR) light, specifically with at least one wavelength selected from the range of 510 nm to 830 nm, to tissues using an optical fiber catheter or transdermal light delivery system. The light can be either single wavelength or multiple wavelength, and is emitted to impinge upon target tissues before, during, or after endovascular therapy.
The problem addressed is the lack of effective clinical therapies for conditioning myocardial or other tissues to prevent or reduce reperfusion injuries that occur due to restoration of blood flow in conditions such as ST-elevation myocardial infarction (STEMI). Reperfusion injury can result in significant damage and currently available therapies do not fully resolve this issue, highlighting the need for cardioprotective approaches that limit such injury.
This method enables direct and targeted delivery of R/NIR light to tissues or blood, and can lead to nitric oxide (NO) generation and tissue salvage, providing tissue protection against reperfusion injury without requiring additional pharmacologic agents. The procedure may be administered concurrently with endovascular therapy, but can also be applied before or after such interventions depending on the clinical scenario.
Claims Coverage
The patent includes one independent claim defining a core inventive method for conditioning tissues to reduce reperfusion injury, supported by dependent claims with additional implementation features.
Illuminating tissues with selected wavelength light to reduce reperfusion injury
A method comprising illuminating a region in a subject containing tissues with light from a light source having at least one wavelength selected from a range of 510 nm to 670 nm, such that the tissues are conditioned by the light and reperfusion injury of the tissues resulting from an endovascular therapy is significantly reduced. - Light source can be broadband or single wavelength within the specified range. - Conditioning by light is directly linked to a significant reduction in reperfusion injury after endovascular therapy.
The inventive feature centers on using light of specific wavelengths to condition tissues against reperfusion injury associated with endovascular therapies.
Stated Advantages
Delivers transient application of far red and near infrared light at the time of endovascular therapy to limit reperfusion injury in end organ tissue.
Promotes nitric oxide (NO) generation and tissue salvage via NO-dependent pathways, without the need for exogenous pharmacological agents.
Provides protection against reperfusion injury by conditioning tissues directly with light, reducing reliance on drugs or other interventions.
Applicable via both optical fiber catheter and transdermal light delivery systems, offering flexibility in clinical use.
Documented Applications
Transcatheter reperfusion of acute myocardial infarction, including percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) and acute coronary ischemia (ACS).
Transcatheter reperfusion of ischemic stroke and/or traumatic brain injury to limit cerebral injury.
Transcatheter reperfusion of the kidneys to limit renal injury during percutaneous renal artery interventions.
Transcatheter revascularization of ischemic limbs for limb salvage and wound healing, improving response to peripheral intra-arterial interventions.
Use with excimer laser systems for protective conditioning of tissues before, during, and/or after plaque ablation procedures.
Use in conjunction with transcatheter supersaturated oxygen (SSO2) delivery systems to limit infarct size and improve myocardial salvage.
Interested in licensing this patent?